---
title: Rehabilitation measures meaningful daily improvements
nct_id: NCT06487364
status: RECRUITING
sponsor: Emre Şenocak
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06487364"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06487364"
last_fetched: "2026-05-10T14:04:24.145Z"
source: "Parkinson's Pathways (curated)"
---
# Rehabilitation measures meaningful daily improvements

**Goal (in five words):** Rehabilitation measures meaningful daily improvements

**Official Title:** Determination of the Minimal Detectable Change and Minimum Clinically Important Change Score of the Parkinson's Disease Questionnaire-8

**Trial ID:** [NCT06487364](https://clinicaltrials.gov/study/NCT06487364)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Emre Şenocak
- **Target Enrollment:** 39 participants
- **Start Date:** 2024-05-13
- **Completion Date:** 2025-01-17
- **Conditions:** Parkinson Disease
- **Interventions:** Rehabilitation
- **Intervention Types:** OTHER

## Summary For Families

The goal is to figure out how much change in the PDQ-8 quality of life score counts as a real, measurable difference and as a meaningful improvement for people with Parkinson's. Participants will take part in a rehabilitation program and complete the PDQ-8 before and after treatment, so researchers can calculate the minimal detectable change and the minimum clinically important change, with the PDQ-8 measuring Parkinson's-related daily life and wellbeing. The study is looking for people aged 40 to 80 with mild to moderate Parkinson's (Hoehn and Yahr stages 1,3), on stable Parkinson's medications with regular neurology follow-up, normal cognition (MMSE >24), and without other neurological disease, recent upper limb surgery or ongoing pain, active mood disorders, substance use, or uncorrectable vision or hearing loss.

## Eligibility

- **Minimum age:** 40 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* Having regular neurology follow-up and using medicine;
* Hoehn and Yahr Scale Stage between 1-3 points;
* Mini-Mental State Assessment Score \>24 points;

Exclusion Criteria:

* Having a secondary neurological disease;
* Any surgery and/or trauma affecting the upper extremity
* Having complaints of pain before the treatment program;
* There was a change in medical treatment during the study;
* With symptoms of anxiety and depression;
* Those who use alcohol and drugs;
* Individuals with vision defects that cannot be corrected by the use of glasses and those with hearing loss
```

## Locations (1)

- Private Güney Hospital, Istanbul, Turkey (Türkiye) _(41.0138, 28.9497)_
  - Call Center, Personel of Call Center — (CONTACT) — +90 212 645 16 16 — bilgiislem@guneyhastanesi.com
  - Adem Aktürk, PhD (Also: Medical Doctor) — (CONTACT) — +90 533 310 23 15 — aakturk@gelisim.edu.tr

## Central Contacts

- Emre Şenocak, PhD — (CONTACT) — +90 553 569 56 92 — emre.senocak@windowslive.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06487364*  
*HTML version: https://parkinsonspathways.com/trial/NCT06487364*  
*Source data: https://clinicaltrials.gov/study/NCT06487364*